Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 21; no. 1; p. 178
• Main Authors: Trepp, Roman, Muri, Raphaela, Abgottspon, Stephanie, Bosanska, Lenka, Hochuli, Michel, Slotboom, Johannes, Rummel, Christian, Kreis, Roland, Everts, Regula
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.02.2020; BioMed Central; BMC
• Subjects: Administration, Oral; Adult; Adults; Amino acids; Blood flow; Brain - diagnostic imaging; Brain - drug effects; Brain - physiopathology; Care and treatment; Child development; Clinical trials; Clinical Trials, Phase IV as Topic; Cognition; Cognition & reasoning; Cognition - drug effects; Cognition - physiology; Cross-Over Studies; Diet; Double-Blind Method; Drug Administration Schedule; Education; Equivalence Trials as Topic; Executive function; Female; Humans; Intervention; Magnetic Resonance Imaging; Male; Medical imaging; Medical research; Medical screening; Memory; Memory, Short-Term - drug effects; Memory, Short-Term - physiology; Metabolism; Neuroimaging; Neuropsychological Tests; Neuropsychology; Newborn infants; Patients; Phenylalanine; Phenylalanine - administration & dosage; Phenylalanine - blood; Phenylketonuria; Phenylketonurias - blood; Phenylketonurias - drug therapy; Phenylketonurias - physiopathology; PKU; Placebos - administration & dosage; Pregnancy; Proteins; Randomized Controlled Trials as Topic; Short-term memory; Spectrum analysis; Study Protocol; Switzerland; Treatment Outcome; Working memory; Switzerland; Neuroimaging; Phenylketonuria; Diet; Phenylalanine; Neuropsychology; PKU; Working memory
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-019-4022-z

The population of adult patients with early-treated phenylketonuria (PKU) following newborn screening is growing substantially. The ideal target range of blood phenylalanine (Phe) levels in adults outside pregnancy is a matter of debate. Therefore, prospective intervention studies are needed to evaluate the effects of an elevated Phe concentration on cognition and structural, functional, and neurometabolic parameters of the brain. The PICO (Phenylalanine and Its Impact on Cognition) Study evaluates the effect of a 4-week Phe load on cognition and cerebral parameters in adults with early-treated PKU in a double-blind, randomized, placebo-controlled, crossover, noninferiority trial. Thirty adult patients with early-treated PKU and 30 healthy controls comparable to patients with regard to age, sex, and educational level will be recruited from the University Hospitals Bern and Zurich, Switzerland. Patients are eligible for the study if they are 18 years of age or older and had PKU diagnosed after a positive newborn screening and were treated with a Phe-restricted diet starting within the first 30 days of life. The cross-over intervention consists of 4-week oral Phe or placebo administration in patients with PKU. The study design mimics a Phe-restricted and a Phe-unrestricted diet using a double-blinded, placebo-controlled approach. The primary objective of the PICO Study is to prospectively assess whether a temporarily elevated Phe level influences cognitive performance (working memory assessed with a n-back task) in adults with early-treated PKU. As a secondary objective, the PICO Study will elucidate the cerebral (fMRI, neural activation during a n-back task; rsfMRI, functional connectivity at rest; DTI, white matter integrity; and ASL, cerebral blood flow) and neurometabolic mechanisms (cerebral Phe level) that accompany changes in Phe concentration. Cognition, and structural and functional parameters of the brain of adult patients with early-treated PKU will be cross-sectionally compared to healthy controls. All assessments will take place at the University Hospital Bern, Switzerland. Central randomization will be used to assign participants to the different treatment arms with age, sex, and center serving as the stratification factors. Randomization lists will be generated by an independent statistician. Blinding: All trial personnel other than the statistician generating the randomization list and the personnel at the facility preparing the interventional product are blinded to the assigned treatment. Using a combination of neuropsychological and neuroimaging data, the PICO Study will considerably contribute to improve the currently insufficient level of evidence on how adult patients with early-treated PKU should be managed. The study is registered at clinicaltrials.gov (NCT03788343) on the 27th of December 2018, at kofam.ch (SNCTP000003117) on the 17th of December 2018, and on the International Clinical Trials Registry Platform of the WHO.